Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Nov 8 - Nov 13
The drug candidate acts as an agonist of the glucagon-like peptide-1 (GLP-1) receptor, following the same mode of action as Mounjaro (tirzepatide), the companys peptide-based GLP-1 drug for weight loss
Got answers quickly
(PubMed) Isaacs E, Oates J
[1] [3] Crucially for weight management, these medications act on receptors in the hypothalamus and brainstem areas that regulate appetite and satiety, leading to reduced hunger, increased feelings of fullness, and decreased food intake
The risk increases with age, with prevalence rising from 1.05% in individuals aged 1830 to 11.6% in those over 70
US$ 28.31
US$ 24.88
US$ 24.97
US$ 27.90
US$ 26.30
US$ 26.97
